Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

NovaBay Pharmaceuticals (NBY) Long-Term Debt Repayments (2016 - 2025)

Historic Long-Term Debt Repayments for NovaBay Pharmaceuticals (NBY) over the last 10 years, with Q1 2025 value amounting to $507000.0.

  • NovaBay Pharmaceuticals' Long-Term Debt Repayments fell 1228.37% to $507000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $506000.0, marking a year-over-year decrease of 8122.45%. This contributed to the annual value of $2.0 million for FY2024, which is 3500.68% up from last year.
  • Latest data reveals that NovaBay Pharmaceuticals reported Long-Term Debt Repayments of $507000.0 as of Q1 2025, which was down 1228.37% from -$1000.0 recorded in Q4 2024.
  • Over the past 5 years, NovaBay Pharmaceuticals' Long-Term Debt Repayments peaked at $791000.0 during Q3 2024, and registered a low of -$1000.0 during Q4 2024.
  • In the last 3 years, NovaBay Pharmaceuticals' Long-Term Debt Repayments had a median value of $577500.0 in 2023 and averaged $496375.0.
  • The largest annual percentage gain for NovaBay Pharmaceuticals' Long-Term Debt Repayments in the last 5 years was 22227.98% (2024), contrasted with its biggest fall of 10014.2% (2024).
  • Over the past 3 years, NovaBay Pharmaceuticals' Long-Term Debt Repayments (Quarter) stood at $704000.0 in 2023, then crashed by 100.14% to -$1000.0 in 2024, then surged by 50800.0% to $507000.0 in 2025.
  • Its Long-Term Debt Repayments stands at $507000.0 for Q1 2025, versus -$1000.0 for Q4 2024 and $791000.0 for Q3 2024.